DBV Technologies S.A. (NASDAQ:DBVT) Stock Now Rated "Moderate Buy" by Sell-Side Brokerages

Key Points

• Analysts rate DBV Technologies “Moderate Buy”: Five of six covering analysts recommend buying, while one recommends selling; the average one-year price target is $45.25. Two brokerages recently cut their targets but maintained positive ratings.
• Institutional ownership is substantial: Hedge funds and other institutions own 71.74% of shares. Vivo Capital increased its stake by 8.4%, and several firms established new positions.
• Quarterly results were mixed: DBV reported a loss of $0.70 per share, worse than the $0.29 loss analysts expected, while revenue of $1.60 million topped the $0.56 million consensus estimate.

Shares of DBV Technologies S.A. (NASDAQ:DBVT - Get Free Report) have earned an average rating of "Moderate Buy" from the six analysts that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $45.25.

A number of research firms have recently commented on DBVT. HC Wainwright reaffirmed a "buy" rating on shares of DBV Technologies in a research note on Friday, October 30th. Guggenheim lowered their target price on shares of DBV Technologies from $51.00 to $46.00 and set a "buy" rating for the company in a research note on Friday, October 30th. Citigroup restated a "market outperform" rating on shares of DBV Technologies in a report on Thursday, October 29th. Citizens Jmp dropped their target price on shares of DBV Technologies from $55.00 to $47.00 and set a "market outperform" rating on the stock in a report on Thursday, October 29th. Finally, Weiss Ratings reaffirmed a "sell (e+)" rating on shares of DBV Technologies in a research report on Thursday, October 15th.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Perceptive Advisors LLC bought a new position in shares of DBV Technologies during the 1st quarter worth approximately $20,146,000. Elmind Capital LP acquired a new stake in shares of DBV Technologies during the 1st quarter worth approximately $5,536,000. Dorsey Wright & Associates acquired a new stake in shares of DBV Technologies during the 1st quarter worth approximately $2,142,000. Diversify Wealth Management LLC bought a new stake in shares of DBV Technologies in the 1st quarter valued at $1,293,000. Finally, Vivo Capital LLC increased its stake in shares of DBV Technologies by 8.4% in the 1st quarter. Vivo Capital LLC now owns 2,667,569 shares of the company's stock valued at $55,726,000 after acquiring an additional 205,943 shares in the last quarter. 71.74% of the stock is owned by institutional investors and hedge funds.

DBV Technologies Stock Performance

Shares of DBVT stock opened at $10.45 on Monday. The stock has a market cap of $657.10 million, a price-to-earnings ratio of -3.47 and a beta of -0.84. The stock has a 50-day moving average of $11.06 and a 200-day moving average of $16.70. DBV Technologies has a 1-year low of $8.63 and a 1-year high of $26.18.

DBV Technologies (NASDAQ:DBVT - Get Free Report) last issued its quarterly earnings data on Wednesday, October 28th. The company reported ($0.70) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.29) by ($0.41). The company had revenue of $1.60 million for the quarter, compared to the consensus estimate of $0.56 million. DBV Technologies had a negative return on equity of 120.95% and a negative net margin of 5,392.17%. Sell-side analysts forecast that DBV Technologies will post -2.22 earnings per share for the current year.

About DBV Technologies

DBV Technologies SA NASDAQ: DBVT is a clinical-stage biopharmaceutical company focused on developing treatments for food allergies and other immune-mediated conditions. The company's approach is based on epicutaneous immunotherapy, which is designed to deliver small amounts of an allergen through the skin to help desensitize the immune system.

DBV Technologies' lead product candidate is Viaskin Peanut, an investigational patch intended to treat peanut allergy, particularly in children.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.